原发性肝癌放疗进展门脉癌栓的放疗.pptVIP

结果 The 1-, 2-, and 3-year pFS for the SG were 32.3, 11.2, and 6.1%, respectively. The 1-, 2-, and 3-year PFS for the RG were 42.2, 24.3, 17.3 %, respectively (p=0.018) . The median and 10.0 months for the SG (p=0.029). OSs were 12.3 months for the RG The 1-, 2-, and 3-year OSs were 51.6, 28.4, and 19.9 %, respectively, for the RG and 40.1, 17.0, and 13.6 %, respectively, for the SG 肝癌合并门静脉癌栓 (PVTT )行3DCRT与外科手术相比有较好的中位生存期、无进展生存率及总生存率。 本文档共84页；当前第61页；编辑于星期一\13点51分 本文档共84页；当前第62页；编辑于星期一\13点51分 本文档共84页；当前第63页；编辑于星期一\13点51分 肝癌伴门静脉/下腔静脉癌栓的放疗 1年生存率:外照射组34.8% 未接受外照射组11.4% Int J Radiat Oncol Bi